NLRP3 and metabolic dysfunction-associated steatotic liver disease: NAFLD is the most common liver disease and there are several studies suggesting that NLRP3 inflammasome, bridging inflammation and fibrosis, could play an important role and potentially representing novel targets for therapy in this disorder18–20.